Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision To Uphold Approval Of Two Generic Versions Of Hetlioz

RefinitivЗаймёт меньше минуты

Vanda Pharmaceuticals Inc VNDA:

VANDA SEEKS FDA COMMISSIONER REVIEW OF OUTGOING CDER DIRECTOR'S DECISION TO UPHOLD APPROVAL OF TWO GENERIC VERSIONS OF HETLIOZ®

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

Чтобы прочитать эту статью, зарегистрируйтесь на TradingView — это бесплатно